Cargando…

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)

Relacorilant is a highly selective glucocorticoid receptor antagonist (GRA) that modulates the effects of excess cortisol while showing no affinity for progesterone, mineralocorticoid, androgen, or estrogen receptors. In a phase 2 study, treatment with relacorilant showed improvement in glycemic and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auchus, Richard, Findling, James, Moraitis, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553349/ http://dx.doi.org/10.1210/js.2019-SUN-451

Ejemplares similares

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome
por: Moraitis, Andreas, et al.
Publicado: (2022)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

THU020 Bilateral Adrenal Hyperplasia (BAH): Undesirable Effect Of Glucocorticoid Receptor Competitive Antagonist (GRCAnt) In Cushing’s Disease
por: Canturk, Ayse, et al.
Publicado: (2023)

SUN-450 Comorbidities in 419 Patients with Cushing's Disease in Remission: A Swedish Nationwide Study
por: Papakokkinou, Eleni, et al.
Publicado: (2019)

ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
por: East, Honey E, et al.
Publicado: (2022)

SUN-452 Predictive Factors of Recurrence in Cushing's Disease after Successful Transsphenoidal Surgery
por: Gomes, Vânia, et al.
Publicado: (2019)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SUN-LB53 Role of the Glucocorticoid Receptor Phosphorylation in Neural Development
por: Silswal, Neeru, et al.
Publicado: (2020)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

SUN-453 Absence of Crooke's Hyaline Changes May Predict Worse Outcomes in Patients with Cushing Disease
por: Akirov, Amit, et al.
Publicado: (2019)

SUN-305 Hair Cortisol Measurement: An Innovative Method for Diagnosis and Follow-Up in Patients with Cushing’s Disease
por: Deligiannis, Natalia Gabriela, et al.
Publicado: (2020)

SUN-LB074 Racial Distribution, Presentation and Outcome in Acromegaly and Cushing's Disease: A Tertiary Referral Center Study in 220 Patients
por: Goswami, Neevedita, et al.
Publicado: (2019)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
por: He, Xin, et al.
Publicado: (2022)

SUN-462 Petrous Sinus Catheterization, Baseline and after Stimulation with Desmopressin, for the Diagnosis of Cushing's Disease, Experience of a National Health Institute in Mexico
por: León-Suárez, Andrés, et al.
Publicado: (2019)

SAT-310 Analysis of the Influence of Glucocorticoid Receptor Gene Polymorphism BCL-1 on Clinical and Psychiatric Manifestations in Brazilian Patients with Cushing’s Disease
por: Garcia, Erica, et al.
Publicado: (2020)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

SAT-256 The Ever Confusing Cushing’s Work Up: Is It Real? Is It Pseudo Cushing’s’? Or Could It Be Factitious
por: Ghalib, Luma, et al.
Publicado: (2020)

Hypercoagulability in ACTH-Dependent Cushing Syndrome
por: Singh Sumal, Amit Kartar, et al.
Publicado: (2021)

Occult Carcinoid Causes Cushing’s Syndrome
por: Meftali, Sabrina, et al.
Publicado: (2021)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

OR06-01 The Role of Germline Defects in Cushing’s Disease
por: Hernández-Ramírez, Laura C, et al.
Publicado: (2020)

SAT-277 A Fierce Presentation of Cushing Disease
por: Al Sabie, Farah Laith, et al.
Publicado: (2020)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison With Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2021)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
por: Lamback, Elisa Baranski, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6pibjljpj0cgbe3f6df048ft57